Relapsed/Refractory Multiple Myeloma Treatment Decision Making

Caitlin Costello, MD, discusses her insights and considerations when choosing the next line of therapy in a patient with relapsed/refractory multiple myeloma.

Dr. Costello explores the mechanism of action (MOA) of talquetamab and its distinctive role in Relapsed/Refractory Multiple Myeloma (R/R MM), drawing comparisons with other bispecific therapies.

An expert briefly reviews the role of GPRC5C-targeting bispecifics in Relapsed/Refractory Multiple Myeloma (R/R MM) following four previous lines of therapy, comparing its efficacy and characteristics with other treatment options like BCMA and CAR-T therapies. She also provides insights into the benefits, risks, and potential challenges related to the access and utilization of GPRC5D-targeting bispecifics, providing a comprehensive overview of considerations in the advanced R/R MM treatment landscape.

Amir Ali, PharmD reviews a clinical scenario in a relapsed/ refractory multiple myeloma patient.

Amir discusses challenges encountered during the administration process, offering valuable perspectives on the practical considerations and complexities in delivering these innovative therapies.

Oncology Clinical Pharmacist Specialist Amir Ali delves into potential challenges related to access and the use of this therapy, providing a comprehensive perspective on the complexities of incorporating GPRC5-targeting bispecifics into R/R MM patient management.

Ursula Linne-Mclaren, RN, reviews a clinical scenario in a relapsed/ refractory multiple myeloma patient.

Nurse Linne-Mclaren provides her insights into the proactive measures, monitoring strategies, and experiences related to talquetamab-associated adverse events, along with a broader perspective on prophylactic measures for managing potential adverse events in bispecific therapies.

Ursula Linne-Mclaren briefly discusses valuable guidance for patients and caregivers, particularly those considering bispecific therapies, providing a supportive perspective on the journey through R/R MM treatment.

Advanced practice providers focus on the case of a patient diagnosed with multiple myeloma who lives in a rural area with limited access to care.